209 related articles for article (PubMed ID: 26512044)
1. Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?
Goldberg RM
Oncologist; 2015 Dec; 20(12):1448-56. PubMed ID: 26512044
[TBL] [Abstract][Full Text] [Related]
2. [Personalized tumor therapy for gastrointestinal tumors].
Ettrich TJ; Perkhofer L; Seufferlein T
Internist (Berl); 2015 Sep; 56(9):1069-78. PubMed ID: 26148698
[TBL] [Abstract][Full Text] [Related]
3. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.
Le Tourneau C; Kamal M; Tsimberidou AM; Bedard P; Pierron G; Callens C; Rouleau E; Vincent-Salomon A; Servant N; Alt M; Rouzier R; Paoletti X; Delattre O; Bièche I
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598514
[TBL] [Abstract][Full Text] [Related]
4. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.
Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW
Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568
[TBL] [Abstract][Full Text] [Related]
5. Translating genomic profiling to gastrointestinal cancer treatment.
Harada K; Mizrak Kaya D; Shimodaira Y; Song S; Baba H; Ajani JA
Future Oncol; 2017 Apr; 13(10):919-934. PubMed ID: 28067073
[TBL] [Abstract][Full Text] [Related]
6. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
7. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.
De Mattia E; Cecchin E; Toffoli G
Drug Resist Updat; 2015 May; 20():39-70. PubMed ID: 26027741
[TBL] [Abstract][Full Text] [Related]
9. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
10. Current trends in clinical genetics of colorectal cancer.
Markovic S; Dimitrijevic I; Zogovic B; Markovic V; Barisic G; Krivokapic Z
J BUON; 2016; 21(5):1042-1049. PubMed ID: 27837603
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for personalized medicine in GI cancers.
Zhang SY; Zhang SQ; Nagaraju GP; El-Rayes BF
Mol Aspects Med; 2015 Nov; 45():14-27. PubMed ID: 26054566
[TBL] [Abstract][Full Text] [Related]
12. From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy.
Palma S; Zwenger AO; Croce MV; Abba MC; Lacunza E
Clin Colorectal Cancer; 2016 Jun; 15(2):104-15. PubMed ID: 26777471
[TBL] [Abstract][Full Text] [Related]
13. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
15. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
16. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
[No Abstract] [Full Text] [Related]
17. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiles in foregut oncology.
Sukharamwala P; Hennessey D; Wood T; Singh S; Ryan C; Rosemurgy A
Cancer Genet; 2016 Dec; 209(12):537-553. PubMed ID: 27887938
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies and predictive markers in epithelial malignancies of the gastrointestinal tract.
McIntire M; Redston M
Arch Pathol Lab Med; 2012 May; 136(5):496-503. PubMed ID: 22229849
[TBL] [Abstract][Full Text] [Related]
20. Reclassifying colorectal cancer subtypes.
Burki TK
Lancet Oncol; 2015 Dec; 16(16):e591. PubMed ID: 26511645
[No Abstract] [Full Text] [Related]
[Next] [New Search]
